<p>Feasibility Study of Adjuvant Chemotherapy with Carboplatin and Nab-Paclitaxel for Completely Resected NSCLC</p>-Reference-Cited by-同舟云学术

Feasibility Study of Adjuvant Chemotherapy with Carboplatin and Nab-Paclitaxel for Completely Resected NSCLC

Published:2020-02 Issue: Volume:Volume 12 Page:777-782
ISSN:1179-1322
Container-title:Cancer Management and Research
language:en
Short-container-title:CMAR

Author:

Katsurada Naoko^ORCID,Tachihara Motoko^ORCID,Hatakeyama Yukihisa,Koyama Kiyoko,Yumura Masako,Kiriu Tatsunori^ORCID,Dokuni Ryota^ORCID,Hazama Daisuke,Tokunaga Shuntaro^ORCID,Tamura Daisuke,Nakata Kyosuke^ORCID,Yamamoto Masatsugu^ORCID,Kamiryo Hiroshi^ORCID,Kobayashi Kazuyuki,Tanaka Yugo,Maniwa Yoshimasa,Nishimura Yoshihiro

Publisher

Informa UK Limited

Subject

Oncology

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic Significance of Tumor Mutation Burden among Patients with Non-small Cell Lung Cancer Who Received Platinum-based Adjuvant Chemotherapy: An Exploratory Study;Journal of Cancer Prevention;2023-12-30

2. Targeted therapy of non-small cell lung cancer and liver cancer: functional nanocarriers for the delivery of cisplatin and tissue factor pathway inhibitor-2;Chemotherapy;2022-11-03

3. Surface-engineered smart nanocarrier-based inhalation formulations for targeted lung cancer chemotherapy: a review of current practices;Drug Delivery;2021-01-01

4. CircRNAs: biogenesis, functions, and role in drug-resistant Tumours;Molecular Cancer;2020-08-05

Influence of Programmed Death Ligand-1-Gene Polymorphism rs822336 on the Prognosis and Safety of Postoperative Patients with NSCLC Who Received Platinum-Based Adjuvant Chemotherapy

;Cancer Management and Research;2020-08